Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
admin 11th September 2018 Uncategorised 0Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up for a “breakthrough” FDA approval—and a key expansion for the latecomer PD-L1 drug.
More: Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Source: fierce